ITB is effective for ambulatory patients with MS, without compromising short-term (1 year post pump implant) walking speed.7,8
27% to 55% of patients showed even an improvement in their walking speed. 7,8
42% to 50% of patients preserved ambulation for several years (5 years) despite the progressive nature of multiple sclerosis. 7,8
Quality of life as measured by the Self Rating Depression Scale (SDS) has significantly improved on average by 21% even after 6 years of follow up. 10
Activity of daily living as measured by the Barthel Index (BI) significantly improved on average by 43%, over a 6 year period. That means with ITB your patients might improve walking, going up stairs, dressing themselves, self hygiene and grooming.10
Patientenvideo Nancy van den Nieuwenhuizen (MS en spasticiteit) - (02:41)
See the device manual for detailed information regarding the instructions for use, the implant procedure, indications, contraindications, warnings, precautions, and potential adverse events. For further information, contact your local Medtronic representative or consult the Medtronic website at www.medtronic.eu. For applicable products, consult instructions for use on www.medtronic.com/manuals. Manuals can be viewed using a current version of any major Internet browser. For best results, use Adobe Acrobat Reader® with the browser.
Atlas of Multiple Sclerosis (online), MS International Federation -2013 update. Available at: https://www.msif.org/about-us/who-we-are-and-whatwe-do/advocacy/atlas/(accessed March 2020).
Oreja-Guevara C, Gonzalez-Segura D, Vila C. Spasticity in multiple sclerosis: results of a patient survey. Int. J. Neurosci. 2013;123(6):400-408
Goodin DS. Survey of multiple sclerosis in Northern California. Northern California MS Study Group. Mult. Scler. 1999;5(2):78-88
Rizzo MA, Hadjimichael OC, Preiningerova J, Vollmer TL. Prevalence and treatment of spasticity reported by multiple sclerosis patients. Mult. Scler. 2004;10(5):589-595.
Arroyo R, Massana M, Vila C. Correlation between spasticity and quality of life in patients with multiple sclerosis: the CANDLE study. Int J Neurosci.2013 Dec;123(12):850-8.
Alonso J, Regidor E, Barrio G, Prieto L, Rodríguez C, de la Fuente L. Population reference values of the Spanish version of the Health QuestionnaireSF-36. Med Clin (Barc). 1998 Oct 10;111(11):410-6.
"Sammaraiee Y, Stevenson VL, Keenan E, Buchanan K, Lee H, Padilla H, Farrell RA. Evaluation of the impact of intrathecal baclofen on the walking ability of people with Multiple Sclerosis related spasticity. Mult Scler Relat Disord. 2020 Sep 20;46:102503. doi: 10.1016/j.msard.2020.102503. Epub ahead of print. PMID: 33032053.
Abbatemarco JR, Griffin A, Jones NG, Hartman J, McKee K, Wang Z, Nagel SJ, Machado AG, Bethoux F. Long-term outcomes of intrathecal baclofen in ambulatory multiple sclerosis patients: A single-center experience. Mult Scler. 2020 Jul 14:1352458520936912. doi: 10.1177/1352458520936912. Epub ahead of print. PMID: 32662728."
Sammaraiee Y, Yardley M, Keenan L et al. Intrathecal baclofen for multiple sclerosis related spasticity: A twenty year experience. Mult Scler Relat Disord. 2018 Oct 15;27:95-100.
Natale M, D’Oria S, Nero VV, Squillante E, Gentile M, Rotondo M. Long-term effects of intrathecal baclofen in multiple sclerosis. Clin Neurol Neurosurg. 2016;143:121-5.